NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

The Effect of Medicare Part D on Pharmaceutical Prices and Utilization

Mark Duggan, Fiona Scott Morton

NBER Working Paper No. 13917
Issued in April 2008
NBER Program(s):   HC   IO   PE

On January 1, 2006, the federal government began providing insurance coverage for Medicare recipients' prescription drug expenditures through a new program known as Medicare Part D. Rather than setting pharmaceutical prices itself, the government contracted with private insurance plans to provide this coverage. Enrollment in Part D was voluntary, with each Medicare recipient allowed to choose from one of the private insurers with a contract to offer coverage in her geographic region. This paper evaluates the effect of this program on the price and utilization of pharmaceutical treatments. Theoretically, it is ambiguous whether the expansion in insurance coverage would increase or reduce pharmaceutical prices. Insurance-induced reductions in demand elasticities would predict an increase in pharmaceutical firms' optimal prices. However, Part D plans could potentially negotiate price discounts through their ability to influence the market share of specific treatments. Using data on product-specific prices and quantities sold in each year in the U.S., our findings indicate that Part D substantially lowered the average price and increased the total utilization of prescription drugs by Medicare recipients. Our results further suggest that the magnitude of these average effects varies across drugs as predicted by economic theory.

download in pdf format
   (211 K)

email paper

A non-technical summary of this paper is available in the August 2008 NBER digest.  You can sign up to receive the NBER Digest by email.

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (211 K) or via email.

Acknowledgments

Machine-readable bibliographic record - MARC, RIS, BibTeX

Published: Mark Duggan & Fiona Scott Morton, 2010. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.

Users who downloaded this paper also downloaded these:
Abaluck and Gruber w14759 Choice Inconsistencies Among the Elderly: Evidence from Plan Choice in the Medicare Part D Program
Kaestner and Khan w16011 Medicare Part D and its Effect on the Use of Prescription Drugs, Use of Other Health Care Services and Health of the Elderly
Heiss, McFadden, and Winter w15392 Regulation of private health insurance markets: Lessons from enrollment, plan type choice, and adverse selection in Medicare Part D
Blume-Kohout and Sood w13857 The Impact of Medicare Part D on Pharmaceutical R&D
Ketcham and Simon w14326 Medicare Part D's Effects on Elderly Drug Costs and Utilization
 
Publications
Activities
Meetings
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us